Concepedia

Prognostic value of CD103+ tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma

Joshua D. Smith, Emily L. Bellile, Susan E. Ellsperman, M.E. Heft-Neal, Jacqueline E. Mann, Andrew C. Birkeland, Rebecca C. Hoesli, Paul Swiecicki, Francis P. Worden, Caitlin A. Schonewolf,

Oral Oncology · 2022 · 10 citations · 22 references

DOIFull text

Open access

Concepts

References

22

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

, , +11

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno et al. · Cell Reports · 2017 · 1.9K citations · Full text

, , +17

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra et al. · The Lancet Oncology · 2016 · 1.7K citations

, , +13

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

, , +11

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Thomas Duhen, Rebekka Duhen, Ryan Montler et al. · Nature Communications · 2018 · 946 citations · Full text

, , +17